Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses
- PMID: 18395306
- DOI: 10.1016/j.vaccine.2008.02.053
Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses
Abstract
There are legitimate concerns that the highly pathogenic H5N1 avian influenza virus could adapt for human-to-human transmission and cause a pandemic similar to the 1918 "Spanish flu" that killed 50 million people worldwide. We have developed pandemic influenza vaccines by incorporating multiple antigens from both avian and Spanish influenza viruses into complex recombinant adenovirus vectors. In vaccinated mice, these vaccines induced strong humoral and cellular immune responses against pandemic influenza virus antigens, and protected vaccinated mice against lethal H5N1 virus challenge. These results indicate that this multi-antigen, broadly protective vaccine may serve as a safer and more effective approach than traditional methods for development of a pandemic influenza vaccine.
Similar articles
-
Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge.Virology. 2009 Dec 20;395(2):182-9. doi: 10.1016/j.virol.2009.09.018. Virology. 2009. PMID: 19836045
-
Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.Vaccine. 2007 May 4;25(18):3554-60. doi: 10.1016/j.vaccine.2007.01.083. Epub 2007 Jan 30. Vaccine. 2007. PMID: 17293015
-
Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.Virol J. 2008 Oct 28;5:131. doi: 10.1186/1743-422X-5-131. Virol J. 2008. PMID: 18957098 Free PMC article.
-
Strategies for developing vaccines against H5N1 influenza A viruses.Trends Mol Med. 2006 Nov;12(11):506-14. doi: 10.1016/j.molmed.2006.09.003. Epub 2006 Sep 29. Trends Mol Med. 2006. PMID: 17011235 Review.
-
Animal models for the preclinical evaluation of candidate influenza vaccines.Expert Rev Vaccines. 2010 Jan;9(1):59-72. doi: 10.1586/erv.09.148. Expert Rev Vaccines. 2010. PMID: 20021306 Review.
Cited by
-
Oral Modeling of an Adenovirus-Based Quadrivalent Influenza Vaccine in Ferrets and Mice.Infect Dis Ther. 2016 Jun;5(2):165-83. doi: 10.1007/s40121-016-0108-z. Epub 2016 Apr 12. Infect Dis Ther. 2016. PMID: 27071663 Free PMC article.
-
Progress on adenovirus-vectored universal influenza vaccines.Hum Vaccin Immunother. 2015;11(5):1209-22. doi: 10.1080/21645515.2015.1016674. Hum Vaccin Immunother. 2015. PMID: 25876176 Free PMC article. Review.
-
Vaccine approaches conferring cross-protection against influenza viruses.Expert Rev Vaccines. 2017 Nov;16(11):1141-1154. doi: 10.1080/14760584.2017.1379396. Epub 2017 Sep 19. Expert Rev Vaccines. 2017. PMID: 28925296 Free PMC article. Review.
-
Non-replicating adenovirus vectors expressing avian influenza virus hemagglutinin and nucleocapsid proteins induce chicken specific effector, memory and effector memory CD8(+) T lymphocytes.Virology. 2010 Sep 15;405(1):62-9. doi: 10.1016/j.virol.2010.05.002. Epub 2010 Jun 16. Virology. 2010. PMID: 20557918 Free PMC article.
-
A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity.Clin Vaccine Immunol. 2009 Nov;16(11):1624-32. doi: 10.1128/CVI.00182-09. Epub 2009 Sep 23. Clin Vaccine Immunol. 2009. PMID: 19776190 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical